Eslicarbazepine acetate as adjunctive treatment in partial‐onset epilepsy

    loading  Checking for direct PDF access through Ovid


Eslicarbazepine acetate (ESL) is a novel, once‐daily, oral anti‐epileptic drug (AED) approved by the US Food and Drug Administration as mono‐ or adjunctive therapy and by the European Medicines Agency as add‐on treatment for partial‐onset seizures (POS) in adult patients. It is a competitive blocker of voltage‐gated sodium channels (VGSC) and a third‐generation, single enantiomer member of the dibenzazepine family, which includes carbamazepine (CBZ) (first generation) and oxcarbazepine (OXC) (second generation).1 In randomized, double‐blind, placebo‐controlled trials, adjunctive ESL at the recommended optimal daily dose of 800‐1200 mg reduced the standardized seizure frequency, increased the response rate and was well‐tolerated.2
The aim of this study was to assess the clinical response to add‐on ESL in real‐world practice by means of the time‐to‐baseline seizure count methodology, and evaluate whether differences existed according to the exposure to older dibenzazepines.

Related Topics

    loading  Loading Related Articles